CA2346333A1 - Compositions et procedes pouvant inhiber des maladies neoplastiques au moyen de composes apparentes a limocitrine et 5-desmethyl-sinensetine - Google Patents

Compositions et procedes pouvant inhiber des maladies neoplastiques au moyen de composes apparentes a limocitrine et 5-desmethyl-sinensetine Download PDF

Info

Publication number
CA2346333A1
CA2346333A1 CA002346333A CA2346333A CA2346333A1 CA 2346333 A1 CA2346333 A1 CA 2346333A1 CA 002346333 A CA002346333 A CA 002346333A CA 2346333 A CA2346333 A CA 2346333A CA 2346333 A1 CA2346333 A1 CA 2346333A1
Authority
CA
Canada
Prior art keywords
limocitrin
administering
carcinoma
effective amount
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002346333A
Other languages
English (en)
Inventor
Robert M. Horowitz (Deceased)
John A. Manthey
Najla Guthrie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
KGK Synergize Inc
USDA-ARS-OTT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KGK Synergize Inc, USDA-ARS-OTT filed Critical KGK Synergize Inc
Publication of CA2346333A1 publication Critical patent/CA2346333A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des compositions et des procédés de prévention et de traitement de maladies néoplastiques et de l'athérosclérose. Des individus très susceptibles de développer une maladie néoplastique ou l'athérosclérose ou déjà atteints de ces maladies et soumis à un traitement classique peuvent être traités avec une dose effective de composés à base de limocitrine, y compris, entre autres, 3,5,7,4'-tétraméthoxylimocitrine, 3,5,7,4'-triméthyl-éther-5-acétate de limocitrine, 3,5,7,4'-tétraméthoxylimocitrine ou 3,7,4'-triméthoxylimocitrine, et 5-desméthyl-sinensétine.
CA002346333A 1998-10-06 1999-10-05 Compositions et procedes pouvant inhiber des maladies neoplastiques au moyen de composes apparentes a limocitrine et 5-desmethyl-sinensetine Abandoned CA2346333A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16763498A 1998-10-06 1998-10-06
US09/167,634 1998-10-06
PCT/US1999/023238 WO2000019998A1 (fr) 1998-10-06 1999-10-05 Compositions et procedes pouvant inhiber des maladies neoplastiques au moyen de composes apparentes a limocitrine et 5-desmethyl-sinensetine

Publications (1)

Publication Number Publication Date
CA2346333A1 true CA2346333A1 (fr) 2000-04-13

Family

ID=22608155

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002346333A Abandoned CA2346333A1 (fr) 1998-10-06 1999-10-05 Compositions et procedes pouvant inhiber des maladies neoplastiques au moyen de composes apparentes a limocitrine et 5-desmethyl-sinensetine

Country Status (5)

Country Link
EP (1) EP1119353A4 (fr)
JP (2) JP2003509334A (fr)
AU (1) AU6291699A (fr)
CA (1) CA2346333A1 (fr)
WO (1) WO2000019998A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6987125B1 (en) 1998-10-06 2006-01-17 The United States Of America As Represented By The Secretary Of Agriculture Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxyflavones
US20060135445A1 (en) * 2003-02-04 2006-06-22 Kabushiki Kaisha Yakult Honsha Breast cancer-resistant protein inhibitor
JP2008513350A (ja) * 2005-05-24 2008-05-01 ケージーケー シナジャイズ インコーポレイテッド フラボノイドとトコトリエノールを含む組成物及びその方法
WO2008035208A2 (fr) * 2006-05-19 2008-03-27 Kgk Synergize Inc Utilisation de flavonoïdes pour inhiber la croissance cellulaire
CN102731459B (zh) * 2012-06-15 2014-05-28 南京中医药大学 灯盏乙素苷元Mannich衍生物及其制备方法和应用
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
KR20230161639A (ko) * 2022-05-19 2023-11-28 제주대학교 산학협력단 제주쑥 추출물을 함유하는 항암용 조성물
CN115813991A (zh) * 2022-11-29 2023-03-21 三峡大学 一种柑橘属果实提取物在制备治疗乳腺癌内分泌药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3867541A (en) * 1972-05-03 1975-02-18 Ralph C Robbins Compositions and methods for disaggregating blood cells
US3903266A (en) * 1972-05-03 1975-09-02 Ralph C Robbins Compositions and methods for disaggregating blood cells
JPH0617304B2 (ja) * 1982-09-09 1994-03-09 理化学研究所 制癌剤
JPH06116164A (ja) * 1992-10-07 1994-04-26 Otsuka Pharmaceut Co Ltd 癌の併用化学療法剤
ZA941290B (en) * 1993-02-26 1995-08-25 Res Dev Foundation Combination cisplatin/tamoxifen therapy for human cancers
US5336685A (en) * 1993-04-12 1994-08-09 Sloan-Kettering Institute For Cancer Research Use of flavonoids to treat multidrug resistant cancer cells
JPH08310952A (ja) * 1995-03-16 1996-11-26 Takeda Chem Ind Ltd 医薬組成物
AU7602896A (en) * 1995-11-07 1997-05-29 Eli Lilly And Company Methods for treating resistant tumors

Also Published As

Publication number Publication date
JP2003509334A (ja) 2003-03-11
AU6291699A (en) 2000-04-26
EP1119353A4 (fr) 2002-08-28
WO2000019998A1 (fr) 2000-04-13
EP1119353A1 (fr) 2001-08-01
JP2005015469A (ja) 2005-01-20

Similar Documents

Publication Publication Date Title
US6251400B1 (en) Compositions and methods of treatment of neoplastic diseases and hypercholesterolemia with citrus limonoids and flavonoids and tocotrienols
US6239114B1 (en) Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols
US6410061B1 (en) Tea catechins as cancer specific proliferation inhibitors
Wiseman The bioavailability of non-nutrient plant factors: dietary flavonoids and phyto-oestrogens
US6410052B1 (en) Tea catechins in sustained release formulations as cancer specific proliferation inhibitors
Codoñer-Franch et al. Citrus as functional foods.
Du et al. Dietary quercetin combining intratumoral doxorubicin injection synergistically induces rejection of established breast cancer in mice
US20090163581A1 (en) Pharmaceutical Products for Treating Neoplastic Disease and Inflammation
US7683095B2 (en) Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxyflavones
CA2346333A1 (fr) Compositions et procedes pouvant inhiber des maladies neoplastiques au moyen de composes apparentes a limocitrine et 5-desmethyl-sinensetine
US7192612B2 (en) Compositions and methods based on synergies between capsicum extracts and tea catechins for prevention and treatment of cancer
EP2575841A2 (fr) Extraits de peau de pomme utilisés pour le traitement des maladies cardiovasculaires
EP1278417A1 (fr) Composition et methodes de traitement, de diminution, et de prevention de maladies et troubles cardio-vasculaires avec des polymethoxyflavones
Ping et al. Taxol synergizes with antioxidants in inhibiting hormal refractory prostate cancer cell growth
Papakotsi et al. Alaska’s Flora as a Treatment for Cancer
Sarkar et al. Citrus and its Fight against Cancer
US20070184132A1 (en) Methods of treating canine osteosarcoma
Guthrie et al. Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxyflavones
Manthey et al. Guthrie et al.
Jones Effects of β-ionone on prostate cancer cells
Juturu et al. Heart protective nutrients: controversy and evidence.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued